Optimal dosing for schizophrenia

Journal of Orthomolecular Medicine

Volumn 20, Issue 2, 2005, Pages 93-99

  Pataracchia, Raymond J ^a  

^a NMRC #411 ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; INOSITOL; NEUROLEPTIC AGENT; NICOTINAMIDE; NICOTINIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

AGRANULOCYTOSIS; APATHY; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIBIDO DISORDER; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; NUTRITION; OPTIMAL DRUG DOSE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

EID: 23044516635     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Toronto Canadian Pharmaceutical Association: Compendium of Pharmaceuticals and Specialties (Canada). 2002 (ed. 37).
2. Pataracchia RJ: Nutritional Management of Schizophrenia. 2003. [Report from the Naturopathic Medical Research Clinic (N.M.R.C.) - available on request.]
3. Baare WF, van Oel CJ, Hulshoff Pol HE et al: Volumes of brain structures in twins discordant for schizophrenia. Arch Gen Psychiatry, 2001; Jan, 58(1): 33-40.
4. Weinberger DR: From neuropathology to neurodevelopment. Lancet, 1995; 346: 552-556.
5. Torrey, EF: Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophrenia Research, 2002; (Dec): 58: 101-115.
6. Hoffer A: Treating chronic schizophrenic patients. J Orthomol Med, 2002; 17(1): 25-41.
7. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC: Subcortical MRI volumes in neuroleptic-niave and treated patients with schizophrenia. Am J Psychiat, 1998; 155: 1711-1717.
8. Chakos MH, Lieberman JA, Bilder RM, et al: Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiat, 1994: 151: 1430-1436.
9. Mazurkiewicz-Kwilecki IM: Possible role of histamine in brain function: neurochemical, physiological, and pharmacological indications. Can J Physiol Pharmacol, 1984 (Jun); 62(6): 709-714.
10. Chouinard G, Vainer JL, Belanger MC et al: Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry, 1994; (Nov) 18(7): 1129-1141.
11. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiat, 1993; (Nov 15), 34(10): 713-738.
12. Jenner P, Marsden CD: Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacol, 1987; Jul, 26(7B): 931-40.
13. Chouinard G, Annable L, Ross-Chouinard A: Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull, 1986; 22(3): 891-896.
14. Rupniak MN, Jenner P, Marsden CD: The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sci, 1983 May 16; 32(20): 2289-311.
15. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry, 1980; (Jan) 137(1): 16-21.
16. Metropolitan King County Council: King County, WA, Ordinance Requiring Psychiatrists to make people well: Passed Oct. 16, 2000. Ordinance 13974. Passed 5/8/00.
17. Rice DP: The economic impact of schizophrenia. J Clin Psychiatry, 1999; 60(Suppl 1): 4-6; discussion 28-30.
18. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE: Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry, 1996; (Apr) 153(4): 519-525.
19. Hoffer A: Should tranquilizers be used preventively for Schizophrenia. J Orthomol Med, 1999; 14(3): 123-127.
20. Sciolla A: Iatrogenic Psychoses. Semin Clin Neuropsychiat, 1998; (Jan) 3(1): 61-69.
21. Winokur G, Zimmerman M, Cadoret R: Cause the bible tells me so. Arch Gen Psychiat, 1988; (Jul) 45(7): 683-684.
22. Hollister LE: Drug-induced psychiatric disorders and their management. Med Toxicol, 1986; (Nov-Dec) 1(6): 428-448.
23. Morrison J, Clancy J, Crowe R, Winokur G: The Iowa 500. I. Diagnostic validity in mania, depression, and schizophrenia. Arch Gen Psychiatry, 1972; (Oct) 27(4): 457-461.
24. Jeste DV, Lohr JB, Eastham JH, et al: Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res, 1998; (May-Aug) 32(3-4): 201-214
25. DeQuardo JR, Tandon R: Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? J Psychiatr Res, 1998; (May-Aug) 32(3-4): 229-242.
26. King DJ: Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr Scand Suppl, 1994; 380: 53-58.
27. Elomaa E: Long-term 'treatment' of schizophrenics with typical neuroleptics: a crime against humanity? Med Hypoth, 1993(Nov); 41(5): 434.
28. Hoffer A: Editorial: The future of psychiatry. J Orthomol Med, 1996; 11(1).
29. Freudenreich O, Goff DC: Polypharmacy in schizophrenia: a fuzzy concept. J Clin Psychiatry, 2003; (Sep), 64(9): 1132; author reply 1132-3.
30. McCue RE, Waheed R, Urcuyo L: Polypharmacy in patients with schizophrenia. J Clin Psychiatry, 2003; (Sep); 64(9): 984-989.
31. Procyshyn RM, Kennedy NB, Tse G, Thompson B: Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry, 2001; (May), 46(4): 334-339.
32. Stahl SM: Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry, 1999 (Jul); 60(7): 425-426.
33. In Boshes, RA & Manschreck, TC: Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophrenia Bull, 2002; 28(2).
34. Hegarty, J, Baldessarini, RJ, Tohen, et al: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiat, 1994; 151: 1409-1416.
35. Carpenter WT, Buchanan RW, Kirkpatrick B, et al: Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiat, 1999; 156: 412-418.
36. Hoffer A: Orthomolecular treatment for Schizophrenia: megavitamin supplements and nutritional strategies for healing and recovery. Los Angeles, CA. Keats Publishing. 1999.
37. Hoffer A: Vitamin B3 and Schizophrenia: Discovery, Recovery, Controversy. Kingston, ON, Canada. Quarry Press. 1998.
38. Hoffer A: Orthomolecular treatment for schizophrenia. Natural Med J, 1999(Mar); 2(3): 12-13.
39. Hoffer A: Editorial: Progress in Psychiatry?: How Many Experiments Are Enough?; Historical Note. J Orthomol Med, 1994; 9(1): 3-6.
40. Hoffer A: Chronic Schizophrenia Patients Treated Ten Years Or More. J Orthomol Med, 1994; 9(1): 7-37.
41. Hoffer A: Correspondence: Follow-up reports on chronic schizophrenic patients. J Orthomol Med, 1994; 121-123.
42. Hoffer A: Orthomolecular Medicine. In. eds. Maksic ZB, Eckert-Maksic M. Molecules in Natural Science and Medicine, An Encomium for Linus Pauling. Chichester, England. Ellis Horwood Ltd. 1991.
43. Hoffer A: Orthomolecular Medicine for Physicians. New Canaan, CT. Keats Publishing. 1989.
44. Hoffer A: Common questions on schizophrenia and their answers. New Canaan, CT. Keats Publishing. 1987: 129-146.
45. Hoffer A: The Adrenochrome Hypothesis of Schizophrenia Revisited. Orthomol Psychiat, 1981; 10(2): 98-118.
46. Hoffer A, Osmond H: Schizophrenia: Another Long Term Follow-up in Canada. Orthomol Psychiat, 1980; 9(2): 107-115.
47. Hoffer A, Osmond H: In reply to the American Psychiatric Association task force report on megavitamins and Orthomolecular therapy in psychiatry, available at: www.iahf.com/orthomolecular/
48. Hoffer A: Natural history and treatment of thirteen pairs of identical twins, schizophrenic and schizophrenic-spectrum conditions. J Orthomol Psychiat, 1976; 5: 101-122.
49. Hoffer A: Mechanism of action of nicotinic acid and nicotinamide in the treatment of schizophrenia. In. eds. Hawkins DR, Pauling L. Orthomol Psychiat, San Francisco. W.H. Freeman and Co. 1973.
50. Hoffer A: Five California schizophrenics. J Schizophren, 1967; 1: 209-220.
51. Hoffer A: Treatment of schizophrenia with a therapeutic program based upon nicotinic acid as the main variable. In. eds. Walaas O. Molecular Basis of Some Aspects of Mental Activity, vol II. New York. Academic Press. 1967.
52. Hoffer A, Osmond H: How to live with schizophrenia. New York, NY. University Books. 1966. [Also published by Johnson, London, 1966.] Revised edition, New York: Citidel Press, 1992. New edition, fall 1997.
53. Hoffer A, Osmond H: The chemical basis of clinical psychiatry. Springfield, IL. C.C. Thomas. 1960.
54. Hoffer A, Osmond H, Callbeck MJ, Kahan, I: Treatment of schizophrenia with nicotinic acid and nicotinamide. J Clin Exper Psychopathol & Quart Rev Psychiat Neurol, 1957 (Jun); 18(2): 131-158.
55. Kelm, Harold; Kelm, Alan. A Further Study of the Validity of the Hoffer-Osmond Diagnostic Test. J Orthomol Med, 1989; 4(4): 4 pp.
56. Hoffer, Abram; Keim, Harold; Osmond, Humphry. The Hoffer-Osmond Diagnostic Test Manual (Revised Edition), 1981. Behavior Sciences Press, 3710 Resource Drive, Tuscaloosa, Alabama 35401, 1-800-826-7223 (A guide for administration and analysis of the HOD Test.)
57. Smythies J: Redox aspects of signaling by catecholamines and their metabolites. Antioxid Redox Signal, 2000 (Fall); 2(3): 575-583.
58. Berge KG, Canner PL: Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol, 1991; 40(Suppl 1): S49-51.
59. Pauling L: How to live longer and feel better. New York, NY. Freeman & Co. 1986.